HomeReal Estate PhotographyCorporate InterviewsCorporate Events | Conventions | ConferencesAV ProductionPortrait Booth ExperiencePhotographyMarketingHeadshotsEventsCP StudioPortfolioMeet the CreativesBlogFAQsContact Us
Biotech and pharma marketing teams don't get to run a standard corporate video brief. Video production for biotech companies has to survive legal review, satisfy a scientific reviewer, and still land with investors, recruits, or a conference audience on a fixed date.
TL;DR
Biotech and pharma marketing teams answer to more reviewers than almost any other client Corcino Productions works with: legal, regulatory affairs, medical science liaisons, and sometimes outside counsel who has never sat through a video shoot. A generic vendor treats that as friction. A partner built for the sector treats it as the brief.
In 2026, biotech companies are producing more video than ever — investor updates, platform explainers, clinical trial recruitment, and employer branding compete for the same lean team's time. The companies that win attention ship video that respects the science and still hits an earnings call or a conference deadline.
This guide is for marketing leads, communications directors, and founders at biotech, pharma, medtech, and life sciences companies who need video a regulatory reviewer will actually approve — not just something that looks good in a pitch deck. If your last project stalled three weeks in legal review, or your last vendor didn't know the difference between a mechanism-of-action animation and a straight marketing explainer, this is written for your next one.
A biotech video isn't done when the edit is locked — it's done when compliance signs off. Ask any vendor how many revision rounds their standard quote includes; if the answer is one, the project will run over budget the moment legal gets involved. Plan for two rounds minimum in 2026, especially on anything referencing clinical data or drug mechanisms.
The script has to be accurate enough for a scientist to approve it and clear enough for an investor or recruit to follow it in one watch. Vendors who write copy first and check the science later produce videos that get rejected in the first review pass. Vendors who script alongside a subject-matter expert produce videos that clear review once.
A production team that has already shot healthcare video production knows what HIPAA-adjacent and FDA-adjacent review cycles look like before day one. That experience shows up as fewer surprise redlines and faster turnaround on the second draft, which matters when a video is tied to an earnings call or a conference date that doesn't move.
Pre-launch pipeline data, unreleased trial results, and lab access all require signed NDAs before a single camera rolls. A production partner who has a standard NDA process ready to go saves a week of legal back-and-forth compared to one who has to draft it from scratch.
Biotech marketing calendars run on external dates: earnings calls, JPMorgan Healthcare Conference, FDA milestone announcements. A vendor who can turn a rough cut in five business days is worth more than one who shoots beautiful footage on a three-week schedule that misses the window.
Corcino Productions ranks these by how often they actually move a biotech or pharma marketing goal, not by production complexity.
Clinical Trial and Mechanism-of-Action Explainer — the credibility builder. Runtime: 90 to 120 seconds. This format typically clears three separate stakeholder review groups — medical, legal, and marketing — before publishing. It's the single most-requested asset for trial recruitment and investor decks in 2026. Verdict: Buy.
Investor and Annual Report Video — the fundraising asset. Pairs directly with the annual report cycle and earnings call calendar. Companies raising in 2026 use this format to compress a 40-page filing into a 3-minute narrative a non-technical investor can actually sit through. Verdict: Buy.
Executive and Scientific Leadership Profile — the trust builder. A 2 to 3 minute format that puts a face and a voice behind the science, which matters more in a sector where trust is the entire sales pitch. It's lower urgency than the two picks above but pays off over a full fundraising or hiring cycle. Verdict: Consider.
Employee Training and SOP Video — the compliance workhorse. Built in modules by department — lab safety, GMP procedures, onboarding — so updates to one SOP don't require reshooting the whole library. This is the format most likely to get cut from a first-year budget and the one that costs the most to skip once an audit happens. Verdict: Buy.
Behind-the-Scenes Lab Culture Video — the recruiting magnet. A social-cut under 60 seconds aimed at LinkedIn and careers pages. It's the lowest-stakes format on this list and the easiest one to deprioritize when timelines get tight. Verdict: Consider.
Plan your 2026 biotech video project
Talk through timelines, review cycles, and format priorities before you brief a vendor.
If the script needs a second legal read before the client sees a rough cut, the timeline was wrong from the start.
Clinical trial / mechanism-of-action explainer
Investor and annual report video
Executive / scientific leadership profile
Employee training / SOP video
Behind-the-scenes lab culture video
What is the best video production for biotech companies in 2026?
Clinical trial explainers and investor videos deliver the strongest return for biotech companies in 2026 because they support fundraising and recruitment directly. Both formats require legal and scientific review before publishing.
How long does biotech video production take with compliance review?
Plan for at least two additional weeks beyond a standard corporate video timeline to cover legal and regulatory review rounds. Projects tied to earnings calls or trial milestones should start production 6 to 8 weeks ahead.
Is in-house video production better than hiring a vendor for pharma companies?
In-house teams rarely have the bandwidth to manage compliance-heavy revision cycles alongside daily marketing work. An outside vendor experienced in regulated industries typically clears review faster because the process is already built into their workflow.
How much does video production for biotech companies cost?
Costs vary by format and revision count, with compliance-driven projects running higher than a standard corporate video due to extra review rounds. Get a project-specific quote rather than relying on a general industry average.
Do biotech companies need NDAs before a video shoot?
Yes, any shoot involving unreleased trial data, pipeline information, or lab access should have a signed NDA in place before filming starts. A production partner with a standard NDA process ready to go saves time compared to drafting one from scratch.
What makes a biotech explainer video effective?
An effective explainer video is accurate enough for a scientist to approve and clear enough for a non-technical investor or recruit to follow in one watch. Scripting alongside a subject-matter expert from the start avoids a rejected first review pass.
Should pharma companies use stock footage in marketing videos?
No, stock lab footage reads as filler to both scientific and investor audiences and undercuts the credibility the video is meant to build. Original footage of actual facilities, staff, or leadership performs better in review and in engagement.
The biotech video projects that stall aren't the ones with bad footage — they're the ones where legal review wasn't scheduled until after the rough cut landed. Build the compliance read into the timeline on day one, not week three, and the rest of the production moves faster than most teams expect in 2026.
